Journal of Drugs in Dermatology articles from November 2006

Journal of Drugs in Dermatology archives from November 2006

Post-herpetic neuralgia: a review of advances in treatment and prevention.
November 1, 2006... Abstract Post-herpetic neuralgia (PHN) is primarily a disease of the elderly and often refractory to treatment. Randomized and controlled trials have yielded several significant advances in the treatment and prevention of this disease....

Multivesicular emulsion: a novel, controlled-release delivery system for topical dermatological agents.
November 1, 2006... Abstract Multivesicular emulsion systems are a new patented technology for topical delivery of pharmaceutical and over-the-counter actives. This novel technology involves the creation of a 2-phase, oil-in-water emulsion system that...

Cosmetic injectable devices: a review of the injection techniques.
November 1, 2006... Abstract An ever increasing number of devices and procedures designed to rejuvenate the aging face are available to dermatologists and plastic surgeons. These devices include products consisting of autologous materials, natural polymers,...

Hyaluronic acid gel in skin rejuvenation.
November 1, 2006... Abstract Hyaluronans have become the most popular agents used for soft tissue augmentation in the entire facial area. They are biodegradeable, nonpermanent and have a remarkable safety profile. Their natural biocompatibility means that no...

The subcutaneous loop: a single suture technique for skin closure after superficial and subcutaneous surgery.
November 1, 2006... Abstract Background: Removal of subcutaneous skin masses and certain deep skin injuries results in defects, which demand immediate closure. Although primary closure of these defects in 2 layers is an acceptable solution, this technique has...

The characteristics and utility of solid phase porous microspheres: a review.
November 1, 2006... Abstract Topical drugs use a variety of ingredients to control the properties of the final product. Solid phase porous microspheres (SPPM, Microsponge[R]) have been incorporated into several topical prescription products in an effort to...

Cutaneous drug reactions associated with newer antiretroviral agents.
November 1, 2006... Abstract Skin is the most commonly affected organ in patients with HIV, and the incidence of cutaneous adverse reactions in persons infected with HIV versus those who are not infected is significantly higher. Cutaneous drug reactions...

Beneficial effect of a moisturizing cream as adjunctive treatment to oral isotretinoin or topical tretinoin in the management of acne.
November 1, 2006... Abstract Despite their beneficial effects on the treatment of acne vulgaris, topical and oral retinoids may cause severe local irritation (retinoid dermatitis) due to their mechanism of action, thereby jeopardizing patient adherence, and...

Nodular vasculitis responsive to mycophenolate mofetil.(CASE REPORTS)
November 1, 2006... Abstract Mycophenolate mofetil is commonly used as a steroid-sparing agent effective in the management of erythema nodosum, idiopathic nodular panniculitis (Pfiefer-Weber-Christian disease), bullous pemphigoid, pemphigus vulgaris, and...

Successful treatment of severe refractory atopic dermatitis with efalizumab.(CASE REPORTS)
November 1, 2006... Abstract Despite multiple therapeutic modalities, treatment of atopic dermatitis with its chronic, relapsing nature remains a challenge. Chronic use of standard therapies is associated with variable efficacy and potential side effects....

Treatment of postoperative soft tissue loss with injectable poly-L-lactic acid.(CASE REPORTS)
November 1, 2006... Abstract We present a case of a 40-year-old woman with a history of a wide local excision for a melanoma and subsequent postoperative soft tissue loss who was successfully treated with injectable poly-L-lactic acid (Sculptra[R]). After...

Orlando Dermatology & Aesthetic Conference.
November 1, 2006... JUNUARY 12-15, 2007 Now in it's 4th year! 212-213-8784 www.orlandoderm.org [ILLUSTRATION OMITTED] REGISTER NOW & SAVE Register before October 25, 2006 with priority code JDDFIVE and SAVE 10%! 2007 Organizing...

Multiple palmar keratoacanthomas treated with acitretin.(CASE REPORTS)
November 1, 2006... Abstract A 62-year-old female presented with multiple keratoacanthomas of the palmar aspects of the hands, wrists, and proximal fingers. Surgery or radiation therapy would have caused significant impairment. A 30-day course of 1 mg/kg per...

Treatment of atypical hidradenitis suppurativa with the tumor necrosis factor receptor-Fc fusion protein etanercept.(CASE REPORTS)
November 1, 2006... Abstract We present a case where etanercept--a soluble tumor necrosis factor receptor-Fc fusion protein--was safe and effective in treating the painful skin lesions of a 24-year-old patient with hidradenitis suppurativa, resulting in an...

Urticarial vasculitis secondary to paroxetine.(CASE REPORTS)
November 1, 2006... Abstract Paroxetine (Paxil) is a widely prescribed antidepressant of the selective serotonin reuptake inhibitor (SSRI) class for which multiple cutaneous adverse effects have been reported, including urticaria, ecchymoses, vasculitis, and...

Elastic net instead of ink to mark BOTOX injection sites for frontal hyperhidrosis.(SURGICAL PEARL)
November 1, 2006... Pearls is a periodic feature that will present brief tips and words of wisdom on techniques in dermatology. Please submit your pearls to: editor@drugsindermatology. Focal hyperhidrosis is a common condition characterized by excessive...

Infliximab proven effective for pyoderma gangrenosum.(WASHINGTON WHISPERS)
November 1, 2006... Infliximab Proven Effective for Pyoderma Gangrenosum Commentary on: Infliximab for the treatment of pyoderma gangrenosum: a randomised, double blind, placebo controlled trial. Brooklyn TN, et al. Gut. 2006;55:505-9. Summary ...

Insufficient evidence is not evidence of insufficiency, beta error in combining topical tacrolimus and narrowband ultraviolet therapy for vitiligo.(WASHINGTON WHISPERS)
November 1, 2006... Insufficient Evidence is Not Evidence of Insufficiency, Beta Error in Combining Topical Tacrolimus and Narrowband Ultraviolet Therapy for Vitiligo Commentary on: A randomized, placebo-controlled, double-blind trial comparing...

Tacrolimus ointment effective for lichen sclerosus.(WASHINGTON WHISPERS)
November 1, 2006... Tacrolimus Ointment Effective for Lichen Sclerosus Commentary on: Multicentre, phase II trial on the safety and efficacy of topical tacrolimus ointment for the treatment of lichen sclerosus. Hengge UR, et al. Br J Dermatol. 2006;...

FDA approves Remicade (infliximab) for psoriasis.(PIPLELINE PREVIEWS)
November 1, 2006... Centocor, Inc, recently announced that the FDA has approved infliximab for the treatment of chronic severe plaque psoriasis. Remicade is an antitumor necrosis factor alpha that is administered directly by caregivers as an intravenous infusion....

Gardasil approved by the European Commission.(PIPLELINE PREVIEWS)
November 1, 2006... Merck's cervical cancer vaccine, Gardasil, was recently approved by the European Commission. Gardasil is a quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) recombinant vaccine and is now the only vaccine in the European Union approved...

Verdeso Foam approved for atopic dermatitis.(PIPLELINE PREVIEWS)
November 1, 2006... Connetics Corporation recently announced that Verdeso Foam (desonide 0.05%) has been approved by the FDA for the treatment of mild to moderate atopic dermatitis. Verdeso Foam will be on the market in the latter part of 2006 and it will be...

FDA approves Algicell Ag wound dressing.(PIPLELINE PREVIEWS)
November 1, 2006... The FDA recently granted approval to Derma Sciences, Inc's new antimicrobial wound dressing. Algicell Ag is a calcium alginate wound dressing with antimicrobial silver. It is composed of 1.4% silver--the concentration that has been shown to...

Contour Threads gains European approval.(PIPLELINE PREVIEWS)
November 1, 2006... Angiotech Pharmaceuticals, Inc, recently announced that its product Contour Threads has been approved for expansion in the European market. Contour Threads is already approved for use in brow, neck, and mid-face lift procedures. These...

Phase III trials for the treatment of hereditary angioedema.(PIPLELINE PREVIEWS)
November 1, 2006... Kos Pharmaceuticals, Inc, recently announced positive preliminary results from 2 Phase III trials of Icatibant for the subcutaneous treatment of hereditary angioedema. Icatibant is a synthetic peptidomimetic that works by blocking the B2...

Phase III clinical trial of Extina (ketoconazole) Foam 2%.(PIPLELINE PREVIEWS)(Clinical report)
November 1, 2006... Connetics Corporation recently announced positive results of a Phase III clinical trial of Extina (ketoconazole) Foam 2% in the treatment of seborrheic dermatitis. This foam is distributed in the vehicle VersaFoam-HF. This study was a...

Telavancin in the treatment of skin and skin structure infections.(PIPLELINE PREVIEWS)
November 1, 2006... Theravance, Inc, recently reported positive results from Phase III trials of Telavancin. Telavancin is a rapidly bactericidal injectable antibiotic that is indicated for the treatment of complicated skin and skin structure infections, namely...

New size for Naftin cream.(PIPLELINE PREVIEWS)
November 1, 2006... Merz Pharmaceuticals recently announced that its product Naftin (naftifine HC1 1%) Cream will now be available in a new 90g size. The product will continue to be available in the previous sizes of 15g, 30g, 60g, and multi-pack with 4 15-g...

Ceftobiprole in the treatment of resistant Staphylococcus aureus skin and skin structure infections.(CLINICAL TRIAL REVIEW)
November 1, 2006... Sponsored by Johnson and Johnson Pharmaceutical Research and Development, L.L.C. The purpose of this study is to compare the clinical cure rate of ceftobiprole medocaril versus a comparator in the treatment of patients with complicated skin and...

T4N5 liposomal lotion in preventing the recurrence of nonmelanoma skin cancer in patients who have undergone a kidney transplant.(CLINICAL TRIAL REVIEW)
November 1, 2006... Sponsors and Collaborators: University of Alabama at Birmingham and National Cancer Institute (NCI). This randomized phase II trial is studying how well T4N5 liposomal lotion works in preventing the recurrence of nonmelanoma skin cancer in...

Photodynamic therapy using silicon phthalocyanine 4 in treating patients with actinic keratosis, Bowen's disease, skin cancer, or stage I or stage II mycosis fungoides.(CLINICAL TRIAL REVIEW)
November 1, 2006... Sponsors and Collaborators: Case Comprehensive Cancer Center and National Cancer Institute (NCI). This phase I trial is studying the side effects and best dose of photodynamic therapy using silicon phthalocyanine 4 in treating patients with...

Celecoxib in preventing skin cancer.(CLINICAL TRIAL REVIEW)
November 1, 2006... Sponsors and Collaborators: Herbert Irving Comprehensive Cancer Center and National Cancer Institute (NCI). The objective of this randomized phase II trial to study the effectiveness of celecoxib in preventing skin cancer in participants...

Gefitinib in treating patients who are undergoing surgery and/or radiation therapy for locally advanced or recurrent squamous cell skin cancer.(CLINICAL TRIAL REVIEW)
November 1, 2006... Sponsors and Collaborators: M.D. Anderson Cancer Center and National Cancer Institute (NCI). Gefitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. This phase II trial is studying how well gefitinib...

Reconstitution with pimecrolimus cream 1% of steroid-damaged skin in adults with atopic dermatitis.(CLINICAL TRIAL REVIEW)
November 1, 2006... Sponsored by Novartis. Topical steroid use may lead to skin deterioration and spider veins. This study will examine long-term management of atopic dermatitis (AD) over 12 months with pimecrolimus cream 1% and its effect on skin reconstitution...

The effect of Efudex treatment on photoaged skin.(CLINICAL TRIAL REVIEW)
November 1, 2006... Sponsor and Collaborator: University of Michigan Valeant Pharmaceuticals International. This study is being done to determine if the expression of p53, a tumor suppressor gene (its activity stops the formation of tumors), is decreased following...

Computer-based continuing education for doctors in examination and counseling of patients on skin cancer or weight control.(CLINICAL TRIAL REVIEW)
November 1, 2006... Sponsors and Collaborators: Rhode Island Hospital Comprehensive Cancer Center and National Cancer Institute (NCI). This randomized clinical trial is studying how well computer-based continuing education courses work in improving doctors'...

Photodynamic therapy in treating patients with skin cancer.(CLINICAL TRIAL REVIEW)
November 1, 2006... Sponsors and Collaborators: Roswell Park Cancer Institute and National Cancer Institute (NCI). Photodynamic therapy uses light and drugs that make cancer cells more sensitive to light to kill tumor cells. This randomized phase II trial is...

Common allergens in skin tests for adult atopic dermatitis.(CLINICAL TRIAL REVIEW)
November 1, 2006... Sponsored by National Taiwan University Hospital. The objective of this study is to analyze the common allergens revealed by skin tests in adult atopic dermatitis patients. Condition Atopic Dermatitis Study ID Numbers:...

Effect of Revival Soy on weight loss and skin, hair, and nails in premenopausal women.(CLINICAL TRIAL REVIEW)
November 1, 2006... Sponsors and Collaborators: Physicians Pharmaceuticals, Inc. and Dermatology Consulting Services. The purpose of this study is to determine if dietary consumption of Revival Soy can improve the appearance of the skin, hair, and finger nails and...

The effects of microdermabrasion on skin remodeling.(CLINICAL TRIAL REVIEW)
November 1, 2006... Sponsored by University of Michigan. This research project aims to study the effects of microdermabrasion, a technique causing minimal injury used to improve the appearance of fine lines, wrinkles, and scars. We are interested in determining...

Comparison of cephalexin versus clindamycin for empiric treatment of suspected CA-MRSA skin infections.(CLINICAL TRIAL REVIEW)
November 1, 2006... Sponsored by Johns Hopkins University. The purpose of this study is to help define the role of antibiotics in the treatment of pediatric skin infections caused by CA-MRSA. We hypothesize that treatment with cephalexin, a penicillin-like...

Topical imiquimod compared with surgery in treating patients with basal cell skin cancer.(CLINICAL TRIAL REVIEW)
November 1, 2006... Sponsored by Cancer Research UK. Biological therapies such as imiquimod use different ways to stimulate the immune system and stop cancer cells from growing. This randomized phase III trial is studying how well topical imiquimod works compared...

Sarcothal: thalidomide in skin sarcoidosis.(CLINICAL TRIAL REVIEW)
November 1, 2006... Sponsors and Collaborators: Assistance Publique--Hopitaux de Paris and Societe Francaise de Dermatologie. The objective of this study is to assess the efficacy and tolerance of thalidomide in skin sarcoidosis. Condition Intervention ...

Study to compare different light therapies (narrowband ultraviolet B versus PUVA) for hand and foot skin diseases.(CLINICAL TRIAL REVIEW)
November 1, 2006... Sponsored by Mayo Clinic. Hand and foot skin diseases, such as dermatitis and psoriasis, that do not respond to topical creams can be treated with ultraviolet light therapy. Topical psoralen plus ultraviolet A (PUVA) is commonly used to treat...

Ultraviolet B (UVB) light therapy in the treatment of skin conditions with altered dermal matrix.(CLINICAL TRIAL REVIEW)
November 1, 2006... Sponsored by University of Michigan. This research study will evaluate the effectiveness of high dose UVB light therapy in the treatment of keloid (or hypertrophic scar), scleroderma, acne keloidalis nuchae, old burn scars, granuloma annulare...

Topical sunscreen in preventing skin rash in patients receiving drugs such as erlotinib or cetuximab for cancer.(CLINICAL TRIAL REVIEW)
November 1, 2006... Sponsors and Collaborators: North Central Cancer Treatment Group and National Cancer Institute (NCI). Topical sunscreen may be effective in preventing skin rash caused by treatment with drugs such as erlotinib or cetuximab. This randomized...

Infliximab (Remicade[R]) to treat dermatomyositis and polymyositis.(CLINICAL TRIAL REVIEW)
November 1, 2006... Sponsored by National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS). This study will examine whether infliximab (Remicade) is safe and effective for the treatment of dermatomyositis and polymyositis. Infliximab blocks the...

Skin cleansing with chlorhexidine to decrease hospital acquired infections.(CLINICAL TRIAL REVIEW)
November 1, 2006... Sponsors and Collaborators: John H. Stroger Hospital and Sage Products, Inc. This study is designed to look at a change in bathing procedure as a method to reduce infections. The goal of this proposed study is to further evaluate the...

Use of infliximab for the treatment of pemphigus vulgaris.(CLINICAL TRIAL REVIEW)
November 1, 2006... Sponsored by National Institute of Allergy and Infectious Diseases (NIAID). Pemphigus vulgaris (PV) is a rare skin disorder that causes blistering of the skin and mucous membranes. This study will determine if infliximab given in combination...

Study to determine if tissue scored with a scalpel results in any noticeable marks.(CLINICAL TRIAL REVIEW)
November 1, 2006... Sponsored by University of California, Davis. Mohs Micrographic Surgery is a well established method for treatment of cutaneous malignancies. Part of this technique requires marking skin surrounding the tumor. There are 2 ways of marking the...